MAPK1 and head and neck squamous cell carcinoma: As EGFR kinase inhibitors (e.g., erlotinib, gefitinib) are known to be clinically safe for treatment of lung cancer, these clinical and findings provide important scientific evidences supportive of precision trials for MAPK1-mutated, yet EGFR-addicted HNSCC.